CRL - Charles River Laboratories International, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs.
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $226.13 and traded as high as $310.53. Charles River Laboratories International shares last traded at $302.7710, with a volume of 941,309
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River's specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.
Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given
Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.
Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations. Institutional and Insider Ownership 99.2% of
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:Morgan Stanley 2
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Amundi trimmed its position in Charles River Laboratories International, Inc. (NYSE: CRL) by 46.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 412,402 shares of the medical research company's stock after selling 360,913 shares during the period.
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.